Regulatory T cells in tumor immunity

By H. Nishikawa, Shimon Sakaguchi. International Journal of Cancer, 2010

955 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/2994d016a878704c394d452464ed648c417eb8c4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

Citations in the corpus

LAG3 (CD223) as a Cancer Immunotherapy Target (2017, background): “Residues: Red = EP residues within the EP motif region; Blue = conserved residues (100%); Purple = semi-conserved residues (>85% - 25/29[4]); Green = dominant residues (>60% - 18/29[11]).”
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors (2013, background): “Importantly, among the CTLA-4þ cells, most were Foxp3þCD25þ cells, representing activated effector Tregs (30, 35, 37), and were PD-1þCTLA-4þ doublepositive cells (Fig.”
Phenotypic and functional specialization of FOXP3+ regulatory T cells (2011, background): “In addition to preventing autoimmunity, T Reg cells regulate immunity to infections of viral, bacterial or parasitic origin, and can also restrain immune responses directed towards tumours or transplanted tissu”
Foxp3 reprograms T cell metabolism to function in low glucose high lactate environments (2017, background): “The suppressive properties of Tregs can also be harnessed by cancers, as tumors acquire mechanisms to evade host immunity (Nishikawa and Sakaguchi, 2010).”
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells (2016, background): “, 2008), are potent suppressors of effector cells and are found at high frequencies in various types of cancers (Fridman et al., 2012; Nishikawa and Sakaguchi, 2010).”
Combining radiotherapy and cancer immunotherapy: a paradigm shift. (2013, background): “CD4 T cells with regulatory function (Treg) also play an important role in inhibiting tumor rejection by direct contact with effector T cells and/or by secretion of immunosuppressive cytokines (86).”
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans (2013, background): “Because activated effector T cells also express CD25, and their production of IL-2 is required for the expansion of CD8 cytotoxic lymphocytes, CD25-based cell depletion may reduce activated effector T cells as well, cancelling the effect of Treg-cell depletion to augment antitumor immunity (10).”
Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells (2012, background): “Tumor-infiltrating T reg cells are enriched in iT reg cells It has long been noted that many tumors harbor Foxp3+ T reg cells (Cao, 2010; Nishikawa and Sakaguchi, 2010; Wilke et al., 2010).”